EGFR and non-small cell lung carcinoma: Many preclinical and clinical studies, as well as a meta-analysis of five clinical trials (Checkmate 017 and 057, Keynote 010, OAK, and POPLAR), showed poor effectiveness of PD-1 inhibitors in patients with EGFR-mutated NSCLC [6,7].